OSI Endorses Apoptosis; Cell Pathways Deal Brings Two Clinical Candidates
OSI Pharmaceuticals is investing in a second oncologic research pathway via the proposed acquisition of Cell Pathways for $32 mil
You may also be interested in...
Roche's outlook for Tarceva in non-small cell lung cancer received a "margin of encouragement" from the Iressa FDA advisory committee review, Pharmaceuticals Head William Burns said on a conference call Oct. 10
Wall Street's muted reaction to Millennium's recent announcements of progress in understanding the genetic basis of obesity illustrates the fickle nature of hype involving biotechnology research.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011